COX-2-specific inhibition: implications for clinical practice.

Document Type

Article

Publication Date

1999

Abstract

Although conventional nonsteroidal anti-inflammatory drugs (NSAIDs) have long been a major therapeutic choice for the management of arthritic conditions, the potential adverse effects of these agents sometimes compromise their clinical utility. New modes of therapy have recently been introduced, and data on the cyclooxygenase-2 (COX-2)-specific inhibitors celecoxib and rofecoxib suggest that these agents will meet the need for safe and effective therapeutic alternatives to conventional NSAIDs.

Publication Title

Journal of the American Osteopathic Association

Volume

99

Issue

11 Suppl

First Page

S18

Last Page

22

Comments

This article was published in Journal of the American Osteopathic Association, Volume 99, Issue 11 Suppl, Pages S18-22.

The published version is available at https://jaoa.org/article.aspx?articleid=2099349 .

Copyright © 1999.

This document is currently not available here.

COinS